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Abstract
Introduction
Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD) can profoundly af-
fect quality of life and are influenced by stress and resiliency. The impact of mind-body inter-
ventions (MBIs) on IBS and IBD patients has not previously been examined.
Methods
Nineteen IBS and 29 IBD patients were enrolled in a 9-week relaxation response based
mind-body group intervention (RR-MBI), focusing on elicitation of the RR and cognitive skill
building. Symptom questionnaires and inflammatory markers were assessed pre- and post-
intervention, and at short-term follow-up. Peripheral blood transcriptome analysis was per-
formed to identify genomic correlates of the RR-MBI.
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Results
Pain Catastrophizing Scale scores improved significantly post-intervention for IBD and at
short-term follow-up for IBS and IBD. Trait Anxiety scores, IBS Quality of Life, IBS Symptom
Severity Index, and IBD Questionnaire scores improved significantly post-intervention and
at short-term follow-up for IBS and IBD, respectively. RR-MBI altered expression of more
genes in IBD (1059 genes) than in IBS (119 genes). In IBD, reduced expression of RR-MBI
response genes was most significantly linked to inflammatory response, cell growth, prolif-
eration, and oxidative stress-related pathways. In IBS, cell cycle regulation and DNA dam-
age related gene sets were significantly upregulated after RR-MBI. Interactive network
analysis of RR-affected pathways identified TNF, AKT and NF-κB as top focus molecules in
IBS, while in IBD kinases (e.g. MAPK, P38 MAPK), inflammation (e.g. VEGF-C, NF-κB) and
cell cycle and proliferation (e.g. UBC, APP) related genes emerged as top focus molecules.
Conclusions
In this uncontrolled pilot study, participation in an RR-MBI was associated with improve-
ments in disease-specific measures, trait anxiety, and pain catastrophizing in IBS and IBD
patients. Moreover, observed gene expression changes suggest that NF-κB is a target
focus molecule in both IBS and IBD—and that its regulation may contribute to counteracting
the harmful effects of stress in both diseases. Larger, controlled studies are needed to con-
firm this preliminary finding.
Trial Registration
ClinicalTrials.Gov NCT02136745
Introduction
Patients with chronic illnesses such as Irritable Bowel Syndrome (IBS) or Inflammatory Bowel
Disease (IBD) often have reduced quality of life. IBS is characterized by abdominal pain/dis-
comfort associated with altered bowel function, such as diarrhea or constipation, without gross
structural changes or inflammation [1]; IBD is characterized by gross inflammation in the gas-
trointestinal (GI) tract which can result in symptoms such as abdominal pain, cramping, diar-
rhea and bloody stools. They are thought to have different underlying pathophysiologic
processes, yet both conditions are believed to be influenced by psychosocial factors, in particu-
lar stress. Therefore, mind-body interventions (MBIs) that are intended to reduce stress may
be promising treatments for these disorders. In the present study, we examine a 9-week relaxa-
tion response-based mind-body intervention (RR-MBI) for a mixed group of IBS and IBD
patients.
Promise of mind-body interventions in GI disease
A number of studies have demonstrated the beneficial impact of non-pharmacological therapies
for IBS, for example, hypnosis, cognitive behavioral therapy (CBT), and stress management edu-
cation [2–4]. Studies suggest that patients with IBS benefit more from CBT treatment than from
routine medical care alone [3]. Relaxation or multimodal therapies (a combination of relaxation
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therapy, education and psychotherapy) have also been shown to be beneficial in IBS [3,5–11]. A
Cochrane review of the literature prior to 2009 noted that psychological interventions taken to-
gether—including CBT, interpersonal psychotherapy and relaxation/stress management—
showed symptom score improvements and improvements in quality of life over the short term
(i.e., 3-months) [12]; however, the durability of these interventions was less clear [13]. Since
2009, a number of larger clinical trials in IBS using a variety of psychological modalities have
confirmed the short-term benefit of both individual and group sessions [4,13–18].
In IBS, studies implicating psychological and psychosocial stressors, heightened stress
responsivity, immune abnormalities, distress-amplifying cognitive styles, psychiatric co-mor-
bidity, and nociceptive abnormalities have led to the formulation of multi-level models which
hypothesize a dynamic interaction between all of these factors. In IBD, similar studies have
suggested that stress may be a risk for IBD flares of all types [19] and that depression may be a
predisposing factor for the development of one of the IBD subtypes, Crohn’s disease [20].
Although less work has been done with non-pharmaceutical treatment for IBD, a small
number of studies have shown a benefit in IBD as well. According to a Cochrane review (2011)
examining the effects of 21 studies using psychotherapy, patient education alone, or multimod-
al interventions in adult patients with IBD, showed no change on health-related quality of life,
coping, emotional state, and disease activity [12]; however, in adolescents there were positive
short-term effects of psychotherapy on most outcomes assessed, including quality of life and
depression. In addition, a recent randomized controlled trial of three relaxation-training ses-
sions and at home practice of guided imagery compared to a wait-list control showed improve-
ments in quality of life and mood, as well as decreases in pain and stress in IBD patients [21].
While there are clear pathophysiological differences between IBS and IBD, in both disorders
chronic pain and negative impacts on psychological well-being can cause patients significant
stress; as a result, treatment for neuropathic pain, anxiety, and depression may be common tar-
gets in both IBS and IBD. These are areas where psychological interventions such as MBIs may
have an impact on both disorders.
The Relaxation Response-Based Mind Body Intervention
The foundation of the RR-MBI used in this trial is elicitation of the relaxation response (RR),
which has been described as a “wakeful hypometabolic” state [22] found to be effective in com-
bating the negative impacts of the stress response, described by Cannon [23] as the “fight-or-
flight” response. The RR is a physiological state characterized by decreased arousal of the sym-
pathetic nervous system [22], and can be elicited using many different techniques, including
breath awareness, guided imagery, meditation, and yoga. RR-MBIs have been shown to reduce
medical symptoms of patients who suffer from chronic medical illnesses [24], facilitate the
elimination of antihypertensive medication among patients with high blood pressure [25], and
lower the risk factors for cardiac events among participants of a cardiac rehabilitation program
[26]. In addition, RR-MBIs appear to be effective in groups made up of patients with many dif-
ferent symptoms and diagnoses [24].
Although MBIs have been investigated and used clinically for many years, their biological
mechanisms of action are just beginning to come to light. A pair of studies by our group exam-
ined differential gene expression in a group of mind-body practice naive participants before
and after 8-weeks of RR-elicitation training (short-term comparison), as well as in naive partic-
ipants before RR-elicitation training compared to a matched group of long-term practitioners
of mind-body techniques (long-term comparison) [27,28]. Dusek et al. (2008) found that more
than 3,000 genes were differentially expressed in the long-term and short-term comparisons.
Using gene set enrichment and interactive network analysis of RR-affected pathways, Bhasin
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et al. (2013) found that decreased expression of the NF-κB gene, along with its upstream and
downstream targets, may be central to beneficial effects of RR elicitation [27]. Other interven-
tions targeting stress (e.g., mindfulness-based stress reduction and cognitive-behavioral stress
management) have been shown to have similar effects on NF-κB and other pro-inflammatory
molecules [29,30]. Such findings, while requiring confirmation in additional studies, are pro-
vocative and suggest genomic changes caused by RR-eliciting practices counter-regulate genes
induced by stress and inflammation.
While RR-MBIs elicit beneficial effects in a variety of medical illnesses, they have not been
tested with IBS and IBD patients. As summarized above, there is good evidence to suggest that
MBIs, like other psychological interventions, may be helpful in IBS. Furthermore, while prior
work has not shown strong evidence for beneficial effects of psychological interventions in
IBD, our recent genomics work demonstrating genetic expression changes in inflammatory
pathways in response to an RR-MBI [27], suggests a mechanism through which MBIs might be
beneficial in IBD. In this pilot study, we examined whether an RR-MBI could be effectively de-
livered to mixed groups of IBS and IBD patients and determined the effects of the intervention
on quality of life, inflammatory markers, and gene expression using transcriptional profiling.
Methods
Study design
This pilot, single center, single-arm, open-label study utilized an RR-MBI for the treatment of
IBS and IBD using elicitation of the RR through meditation techniques and cognitive skill
building, as established by the Benson-Henry Institute for Mind Body Medicine at the Massa-
chusetts General Hospital (BHI). The protocol for this trial and supporting TREND checklist
are available as supporting information; see S1 TREND Checklist and S1 Protocol. All study
procedures were approved by the Partners Healthcare/Massachusetts General Hospital Institu-
tional Review Board. The study was not initially registered on ClinicalTrials.gov given that it
was not a randomized clinical trial (and registration was not required for such studies when it
was initiated in 2009); however, because of changes in registration requirements, the study was
subsequently registered on ClinicalTrials.gov. The authors confirm that all ongoing and related
trials for this intervention are registered.
Participants
Patients with documented IBS (confirmed by the Rome III diagnostic criteria for 6 months) or
IBD (upper limit for HBI [Harvey-Bradshaw index] = 20, upper limit of SCCAI [simple clinical
colitis activity index] = 18) by their primary care provider or gastroenterologist were eligible to
participate. Patients with IBS were excluded if they had abdominal surgery in the past 5 years
(with the exception of appendectomy, cholecystectomy) or documentation of GI motility dis-
order. Patients with IBD were excluded if they used NSAIDS chronically, were on a prednisone
dose20 mg/day, or if surgery was anticipated in the 10-weeks following enrollment. Patients
were also excluded if they had current evidence of duodenal ulcer, gastric ulcer, diverticulitis,
esophagitis or infectious gastroenteritis, or any acute gastrointestinal process, as well as if con-
current total parental nutrition or tube feeding were being used. Patients with recent (within
the last 4-weeks) changes in IBS/IBD medications, planned changes in diet, or current use of
steroids were excluded.
Eligible patients were 18–75 years old and fluent in English. Patients who were pregnant or
attempting to become pregnant were excluded. Patients were excluded if they were currently
(>3-weeks) practicing Tai Chi, meditation, yoga, individual mind/body based psychotherapy
or counseling, as well as if they had initiated psychotherapy within the last 8-weeks, used
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psychotropic medications (except at stable doses for at least 12-weeks), or had an untreated
psychiatric disorder.
Patients were recruited from the Massachusetts General Hospital (MGH) Gastrointestinal
Clinic and from a network of primary care providers at via provider referral, self-referral, and
advertisements posted in waiting areas starting in June, 2009. Potential participants were pre-
screened over the phone by a research nurse and were scheduled for a screening visit, where
written informed consent was obtained and interviews were conducted by a psychologist to de-
termine eligibility. Participants continued to receive standard care related to their IBS/IBD dur-
ing participation in the study.
Intervention
The RR-MBI involved a 9-week group program conducted by a nurse practitioner or psycholo-
gist skilled in MBI, which included a GI-specific session conducted by a physician. The groups
met once weekly for 1.5 hours. Three consecutive, mixed-disorder groups, ranging in size from
10 to 18 participants each, were included in the study, conducted between 9/23/2009 and 5/31/
2011 with follow-up completion by 6/30/2011. The program was multidimensional and includ-
ed daily elicitation of the RR using a variety of methods (including breath focus, single-pointed
focus, imagery, contemplation, yoga, and mindful awareness); cognitive reappraisal skills,
health enhancing behaviors, and the promotion of optimism and acceptance. As described in
Table 1, sessions 1–4 focused on developing an understanding of stress physiology and the
physiology of the RR, its relationship to the digestive system, and developing a regular practice
of eliciting the RR. Sessions 5–9 included information on lifestyle behaviors and the develop-
ment of cognitive skills to cope with stress. Throughout the course of treatment, participants
were asked to elicit the RR at home each day for 15–20 minutes.
Measures
Participants were assessed at baseline and weeks 5 (mid-intervention), 10 (post-intervention),
and 13 (short-term follow-up).
Self-Report Measures. To measure symptoms common to IBS and IBD, the State-Trait
Anxiety Inventory (STAI-Y), the Pain Catastrophizing Scale (PCS), and the Brief Pain
Table 1. The syllabus for the relaxation response-based groupmind body intervention (RR-MBI) for ir-
ritable bowel syndrome or inflammatory bowel disease.
Session Content
Session 1 Overview of Mind-Body Medicine / The Stress Response & The RR
Session 2 Diaphragmatic Breathing / Mini-Relaxation Exercises / Appreciation
Session 3 Mindfulness / Self-Care (Pacing Activities)
Session 4 Introduction to Cognitive Skills / Lifestyle Behaviors: Nutrition
Session 5 Cognitive Restructuring / Cognitive Distortions / Lifestyle Behaviors: Exercise
Session 6 GI Physician Lecture and Q & A
Session 7 Cognitive Skills / RR for Insight / Introduce Journaling Exercise
Session 8 Problem Solving and Communication Skills / Yoga
Session 9 Relapse Prevention
Session content varied by week but always included an activity that elicited the relaxation response (RR)
and a discussion of the homework from the previous week. Homework for the sessions included eliciting
the RR daily, daily mini-relaxation exercises, ﬁlling out a diary sheet, making an entry in an appreciation
journal, and practicing cognitive restructuring exercises and other skills previously learned.
doi:10.1371/journal.pone.0123861.t001
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Inventory (BPI) were administered at each assessment. The STAI-Y is a widely used instru-
ment for measuring anxiety in adults. It differentiates between the temporary condition of
“state anxiety” and the more general and long-standing quality of “trait anxiety” [31]. The PCS
is widely used to assess cognitive and affective responses to pain and to evaluate pain manage-
ment program outcomes [32]. The BPI allows patients to rate the severity of their pain (BPI-S)
and the degree to which their pain interferes with common dimensions of feeling and function
(BPI-I) [33].
At each assessment, participants were also administered validated disease-specific instru-
ments—the IBS Quality of Life (IBS-QOL), the IBS Symptom Severity Index (IBS-SSI), and the
IBD Questionnaire (IBD-Q)—to assess the disease-specific impact of the intervention. The
IBS-QOL is a self-reported quality of life (QOL) measure containing 34 questions specific to
IBS that is used to assess the impact of IBS and its treatment on QOL [34]. The IBS Symptom
Severity Index (SSI) is a widely used questionnaire measuring IBS-related pain frequency, se-
verity of pain, bloating, bowel habit dissatisfaction and interference with daily life and extra-co-
lonic symptoms on a visual analogue scale [35]. The IBD-Q is a 32-question instrument
designed to measure the effects of inflammatory bowel disease on daily function and quality of
life [36]. All information from this study have been deposited in the NIH Gene Expression
Omnibus database at www.ncbi.nlm.nih.gov/geo under the accession number GSE66824.
Biological Samples. Blood was collected at baseline and week-10 for erythrocyte sedimen-
tation rate (ESR) and C-reactive protein (CRP) assays as measures of inflammation and in
PAXgene (Qiagen) tubes for transcriptional expression profiling.
Transcriptional profiling
Total RNA was isolated from whole blood samples collected in PAXgene tubes as described
previously [28]. The peripheral blood gene expression profile was assessed on IBS and IBD pa-
tients with paired pre- and post-intervention samples using HT U133 Plus PM Array plates
(Affymetrix, Santa Clara, CA) containing>54,000 probes, allowing for the analysis of>33,000
well-characterized human genes. Microarray analysis was conducted by the BIDMC Genomics,
Proteomics, Bioinformatics and Systems Biology Center at the Beth Israel Deaconess Medical
Center according to the standard Affymetrix protocol using the high-throughput Affymetrix
GeneTitan system. The quality of hybridized chips was assessed using Affymetrix guidelines on
the basis of perfect match (PM) probes mean, 3' to 5' ratios for beta-actin and GAPDH and val-
ues for spike-in control transcripts. Reproducibility of the samples was checked by using chip-
to-chip correlation and signal-to-noise ratio (SNR) methods for replicate arrays using array-
QualityMetrics, a Bioconductor package in R [38]. All of the high quality arrays were included
for unsupervised and supervised bioinformatics analysis. The transcriptome data along with
information from this study have been deposited in the NIH Gene Expression Omnibus data-
base at www.ncbi.nlm.nih.gov/geo under the accession number GSE66824.
Data analysis
Self-Report Measures. Baseline differences between disease subgroups and between par-
ticipants with and without follow-up data were compared by one-way ANOVA and Fisher’s
exact test. Missing responses to individual questions from multi-question instruments were
completed by single imputation from the observed covariance among all questions, adjusted
for visit. Six of 87 IBDQ, 1 of 56 IBS-QOL, 1 of 56 IBS-SSI, 1 of 148 BPI-Severity, and 9 of 148
PCS instruments required imputation; in 12 of 18 cases for a single missing response. Self-re-
port measures were analyzed in linear mixed models with fixed effects of visit (4 levels) and
random participant-specific intercepts and slopes with unstructured covariance. Contrasts
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were used to estimate change from baseline to week-10 (primary endpoint) and to week-13
(short-term persistence). Changes in symptoms and markers of inflammation were compared
by Pearson correlation. All participants were included in these analyses, including those lost to
follow-up. Estimates from the mixed model would be unbiased if loss to follow-up were pre-
dictable from observed baseline data. As a sensitivity analysis, participants with missing data
were assumed to have experienced no change from baseline. These 10-week change scores with
imputed zeros were analyzed by one-sample Wilcoxon signed rank test.
Transcriptome Profile. Expression data were preprocessed using the Robust Multichip
Average (RMA) method in R using Bioconductor and associated packages. RMA performed
background adjustment, quantile normalization and final summarization of oligonucleotides
per transcript using the median polish algorithm [37]. Batch effects were removed using Com-
Bat, an empirical Bayes method [38]. Probes with absolute maximum expression intensity val-
ues of 10 were removed. When comparing pre- vs. post-intervention samples, differentially
expressed genes were defined as those with p-value<0.05 by two-tailed Student’s t-test and ab-
solute fold change greater than 1.2.
Gene Ontology (GO) analysis. To identify over-represented GO categories in differential-
ly expressed genes, we used the Biological Processes and Molecular Functions Enrichment
Analysis available from the Database for Annotation, Visualization and Integrated Discovery
(DAVID) [39]. DAVID is an online implementation of the EASE software that produces a list
of over-represented categories using jackknife iterative re-sampling of the two-tailed Fisher
exact probabilities. A p-value gets assigned to each category on the basis of enrichments.
Smaller p-values reflect increasing confidence in over-representation. The GO categories with
p-values<0.01 and at least 3 genes were considered significant.
Pathway and Interactive Network analysis. Ingenuity Pathway Analysis (IPA 8.0, Qia-
gen) was used to identify the pathways and interaction networks significantly affected by genes
that are altered after the RR-MBI in IBS and IBD patients. The knowledge base of this software
consists of functions, pathways and network models derived by systematically exploring the
peer reviewed scientific literature. A detailed description of IPA analysis is available at the Inge-
nuity Systems’ web site (http//www.ingenuity.com). It calculates a p-value for each pathway ac-
cording to the fit of users’ data to the IPA database using one-tailed Fisher exact test. The
pathways with p-values<0.01 were considered significantly affected.
For each network, IPA calculates a score derived from the p-value of one-tailed Fisher exact
test [score = -log(p-value)] and indicates the likelihood of focus genes appearing together in
the network due to random chance. A score of 2 or higher has at least a 99% probability of not
being generated by random chance alone. The ability to rank the networks based on their rele-
vance to the queried data sets allows for prioritization of networks with the strongest associa-
tion with pre- to post-intervention changes.
Gene Set Enrichment Analysis. In addition to individual gene analysis, Gene Set Enrich-
ment Analysis (GSEA) was performed. GSEA was used to determine whether a priori defined
sets of genes showed statistically significant, concordant differences between pre- and post-in-
tervention samples [40]. GSEA can be more powerful than single-gene methods for studying
the effects of interventions such as the RR-MBI, in which many genes each make subtle contri-
butions. The gene sets with nominal p-value (NPV) less than 0.005 and a False Discovery Rate
(FDR) less than 7.5% after 500 random permutations were considered significantly altered.
The enriched gene sets were merged into functional modules on the basis of overlap of signifi-
cantly enriched genes using the Enrichment Map [41] Cytoscape Plugin: An Open Source Plat-
form for Complex Network Analysis and Visualization [42].
Leading edge analysis. The significantly enriched genesets or pathways identified from
the GSEA analysis described above can have significant overlap in terms of core-enriched
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genes that are potentially linked to enrichment of multiple genesets. “Leading edge” analysis
considers genes shared across the gene sets which are most strongly associated with the pheno-
type or key effects of the intervention. We used leading edge analysis to cluster significant gene-
sets and identify common genes which accounted for the core enrichment signal. The core set
of genes identified by leading edge analysis is considered the most promising one to generate
hypotheses about the mechanism of an intervention [40].
Results
Nineteen IBS (79% female, mean age 48.3±16.4) and 29 IBD (59% female, mean age 40.5±17.6)
patients were enrolled. Four IBS and 5 IBD patients withdrew during the program after 1 to 3
sessions (Fig 1). Baseline characteristics of patients who withdrew and had no follow-up data
had lower trait scores on the State Trait Anxiety Index and higher CRP levels but were not
Fig 1. CONSORT Enrollment diagram.
doi:10.1371/journal.pone.0123861.g001
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otherwise statistically different than those with all or some follow-up data. All participants
were included in analyses. Additionally, there were no major differences in baseline character-
istics between disease subtypes. The majority of patients were white (96%), single (54%), and
had either some college or a bachelor’s degree (52%) or post-graduate education (38%)
(Table 2). No adverse events due to the RR-MBI were reported.
Self-report measures
Mean changes in the self-report measures from pre- to mid- (week-5) and to post-intervention
(week-10), as well as follow-up (week-13), are presented in Table 3 (for further details, includ-
ing standard errors, please see S1 Table). PCS improved in both disease groups from baseline
to week-13 (from 10.7 at baseline to 5.0 at week-13, p = 0.02 for IBS and from 14.8 to 9.6,
p<0.01 for IBD, Fig 2). STAI trait anxiety improved in both groups from baseline to week-10
(from 39.0 to 33.7, p = 0.02 for IBS and from 39.3 to 33.6, p<0.01 for IBD). These improve-
ments persisted at short-term follow-up (p = 0.02 for IBS and IBD, Fig 3). BPI measures did
not change in either group (p = 0.42 for severity, p = 0.30 for interference).
IBS-QOL scores increased from a mean of 67.1 at baseline to 74.8 at week-10 (p = 0.01), and
to 80.6 at week-13 (p<0.001) suggesting clinical improvement (Fig 4A). IBS-SSI scores decreased
significantly, demonstrating improvement in symptoms, from a mean of 215 at baseline to 154
at week-5 (p<0.01), 128 at week-10 (p<0.001), and 147 at week-13 (p = 0.01, Fig 4B). IBD-Q
Table 2. Baseline characteristics of participants.
All Irritable Bowel Inﬂammatory
Participants Syndrome Bowel Disease
N = 48 N = 19 (40%) N = 29 (60%)
% N % N % N
Gender (%)
Female 67 32 79 15 59 17
Male 33 16 21 4 41 12
Race/Ethnicity (%)
White 96 46 95 18 97 28
Other 4 2 5 1 3 1
Education (%)
High-school 10 5 11 2 10 3
Some College/Bachelors 52 25 42 8 59 17
4-year degree 38 18 47 9 31 9
Marital status (%)
Single/Never married 54 26 58 11 52 15
Married 38 18 32 6 41 12
Divorced/Widowed 8 4 10 2 7 2
Diagnosis Subtypes*
IBS Subtypes Constipation 15 7 37 7
Diarrhea 15 7 37 7
Mixed 10 5 26 5
IBD Subtypes Crohn's Disease 25 12 41 12
Ulcerative Colitis 35 17 59 17
*No signiﬁcant differences were found at baseline between subtypes of IBS and IBD, respectively.
doi:10.1371/journal.pone.0123861.t002
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scores increased, suggesting clinical improvement, from a mean of 171 at baseline to 185 at
week-10 (p<0.01) and remained at 184 at week-13 (p = 0.02, Fig 4C).
In both disease groups, estimated changes over 10 weeks were still significant when treating
all drop-outs or missing assessments as unchanged from baseline.
Biological Measures
Serum inflammatory markers. ESR and CRP did not change significantly for either IBS
or IBD patients. In addition, no changes in psychological measures correlated with ESR/
CRP changes.
Baseline gene expression differences between IBS and IBD. At baseline, 564 significantly
differentially expressed transcripts (p0.05 and absolute fold change [AFC]1.2) distin-
guished IBS from IBD patients (S2 Table). A heatmap depicting the pattern of these differen-
tially expressed transcripts is shown in Fig 5A and suggests that in IBD significantly more of
these differentially expressed genes are upregulated in comparison to IBS. Functional enrich-
ment analysis of these differentially expressed genes indicates significant overrepresentation
(multiple test corrected [43] p<0.05) in inflammatory and antimicrobial response, as well as
inflammatory and hematological disease, RNA post-transcriptional modification, cell cycle,
cell proliferation, and molecular transport (Fig 5B). Pathway analysis suggests that some of
these genes are linked to DNA damage response, MAPK signaling, PPAR-γ activation, interfer-
on signaling and endoplasmic reticulum stress pathways (Fig 5C).
Genomic alterations induced by the RR-MBI in IBS patients. A total of 191 transcripts
were significantly differentially expressed (AFC1.2 and p0.05) post-intervention compared
to pre-intervention. A heatmap depicts the relative expression levels of the selected top differ-
entially expressed genes (Fig 6A). The highest-ranking GO clusters of biological processes and
metabolic functions enriched in these RR-MBI response genes based on analysis by DAVID
are shown in S4 Table. Stress/inflammatory response is the most highly enriched GO cluster
Table 3. Outcomemeasures after intervention and at 3-week follow-up for irritable bowel syndrome (IBS) (N = 19) and inflammatory bowel disease
(IBD) (N = 29).
Irritable Bowel Syndrome Baseline
(Pre-Intervention)
Week 5
(Mid-Intervention)
Week 10
(Post-Intervention)
Week 13
(Short-Term Follow-Up)
Overall P-
value
Pain Catastrophizing Scale (PCS) 10.7 12.2 10.0 5.0* 0.021
State-Trait Anxiety Inventory(STAI-Y)—State
Anxiety
37.2 35.8 31.6 30.8 0.18
State-Trait Anxiety Inventory(STAI-Y)—Trait
Anxiety
39.0 35.9 34.3* 33.7* 0.034
IBS Quality of Life (IBS-QOL) 67.1 71.5 74.8* 80.6*** 0.009
IBS Symptom Severity Index (IBS-SSI) 215.0 153.7** 127.5*** 147.1* 0.002
Inﬂammatory Bowel Disease
Pain Catastrophizing Scale (PCS) 14.8 14.0 10.6* 9.6* 0.003
State-Trait Anxiety Inventory(STAI-Y)—State
Anxiety
36.9 36.0 31.6 31.7 0.14
State-Trait Anxiety Inventory(STAI-Y)—Trait
Anxiety
39.3 36.6 32.4** 33.6* 0.012
IBD Questionnaire (IBD-Q) 171.2 172.0 185.0** 184.3* 0.01
*P<0.05
**P<0.01
***P<0.001
Indicate mixed model analysis estimating change from baseline scores
doi:10.1371/journal.pone.0123861.t003
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and includes the selected processes of cellular response to stress and inflammatory response.
Pathway enrichment analysis using IPA tools identified significant associations (Fisher’s Exact
test p-value<0.05) with integrin and endocytosis signaling, nNOS signaling, paxillin signaling,
tryptophan degradation signaling, NF-κB activation and glutathione redox reaction II (Fig 6B).
Interactive Network analysis of RR-MBI-induced gene expression changes in IBS identi-
fies networks and key nodes related to cell cycle, cellular proliferation, hematological sys-
tems, and inflammation (Details S1 Protocol). The analysis of interactive network based on
number of interactions identified multiple key nodes that include UBC, PI3 Complex, TNF,
AKT, NF-κB complex, TP53 and IFNβ.
Fig 2. Pain Catastrophizing Scale scores at each of the four time points in Irritable Bowel Syndrome
(IBS, light bars, top) and Inflammatory Bowel Disease (IBD, dark bars, bottom). *p<0.05, **p<0.01.
doi:10.1371/journal.pone.0123861.g002
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The RR-MBI upregulates gene sets related to cell cycle, electron transport chain and
DNA Damage and Repair in IBS: Gene set enrichment analysis comparing expression
changes from week-10 to baseline. GSEA analysis identified 78 pathways that were signifi-
cantly (p<0.005, FDR<0.075) altered following the RR-MBI (S1 Fig). The significantly altered
pathways include a cluster related to cell cycle (e.g., mitotic cell cycle, cell cycle checkpoint, cell
cycle M-G1 transition phase), DNA Damage and Repair (e.g., nucleotide excision repair, telo-
mere extension, spliceosome), primary metabolism (e.g., amino acid metabolism, cholesterol
biosynthesis), electron transport chain and muscle contraction. The GSEA analysis shows that
Fig 3. State-Trait Anxiety Inventory (STAI)—Trait scores at each of the four time points. STAI—Trait
scores at each of the four time points in Irritable Bowel Syndrome (IBS, light bars, top) and Inflammatory
Bowel Disease (IBD, dark bars, bottom). (*p<0.05, **p<0.01).
doi:10.1371/journal.pone.0123861.g003
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cell cycle and DNA damage-related pathways are mostly upregulated in IBS patients after
10-weeks of RR-MBI (S2 Fig).
Genomic alterations induced by the RR-MBI in IBD patients. The RR-MBI resulted in
significant differential expression of 1,059 transcripts in IBD patients. Around 73% of these
genes were downregulated. The number of transcripts with altered expression following the
RR-MBI in IBD was much higher (1059) than in IBS (191). A heatmap of selected genes altered
by the RR-MBI is shown in Fig 7A, revealing a clear distinction between the subjects before
Fig 4. Disease-specific quality of life and symptommeasures at each of the four time points. A) Irritable Bowel Syndrome Quality of Life (IBS-QOL)
scores; lower scores indicate improvement. B) Irritable Bowel Syndrome Symptom Severity Index (IBS-SSI) scores; lower scores indicate improvement. C)
Inflammatory Bowel Disease Questionnaire (IBD-Q) scores; higher scores indicate improvement. *p<0.05, **p<0.01, ***p<0.001.
doi:10.1371/journal.pone.0123861.g004
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Fig 5. Transcriptional differences between IBS and IBD patients at baseline, pre-intervention, shown by A) a heatmap of significantly differentially
expressed genes, B) functional categories enrichment analysis, and C) pathways enrichment analysis. A) Relative Gene expression difference
between IBD and IBS for significantly differentially expressed genes are shown with a pseudocolor scale (-1 to 1) with red color denoting higher gene
expression among IBD patients and green color denoting higher expression among IBS patients. The rows represent the genes and columns represent
individual patients. A large fraction of differentially expressed genes were found to be upregulated in IBD patients at baseline relative to IBS patients. B)
Selected top functional categories of differentially expressed genes. The Y–axis represent functional categories and X-axis-log transformed P value (i.e., a
value of 2 represents a P value of. 01), C) Selected pathways of by differentially expressed genes. The Y—axis represent pathways and X-axis-log
transformed P value.
doi:10.1371/journal.pone.0123861.g005
Fig 6. Transcriptional changes and significantly affected pathways for IBS patients pre- to post-mind
body intervention. A) Heatmap of selected top differentially expressed genes identified by comparing pre- to
post-mind body intervention transcriptional profiles. Gene expression is shown with a pseudocolor scale (-1
to 1) with red color denoting increased gene expression post-intervention and green color denoting
decreased expression post-intervention. The rows represent the genes and columns represent individual
subjects in IBS group. B) Top pathways of genes with altered expression among IBS and IBD patients.
Pathway enrichment analysis was performed on differentially expressed genes and significance of effect on
pathway was determined using Fisher’s Exact Test p value. Each bar represents a significantly enriched
pathway. The p value is depicted as −log10 (p value) on primary X-axis.
doi:10.1371/journal.pone.0123861.g006
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and after the RR-MBI. Among the genes that were reduced in expression upon completion of
the RR-MBI, there are several genes which have been directly implicated in inflammatory pro-
cesses that play a critical role in IBD, particularly several genes involved in interferon regula-
tion and signaling. For example, cortactin (CTTN, Fig 7A), an actin-binding protein, is
required for endothelial barrier functions, vascular permeability, neutrophil recruitment, and
leukocyte adhesion and extravasation during inflammation [44]. The GTPase RAB11A (Fig
7A) is involved in recruitment of TLR4 to phagosomes and IRF3 signaling, both of which are
key events in the innate immune response and host defenses against bacterial infection and are
highly relevant for IBD [45]. Several endoplasmic reticulum (ER) stress markers involved in
the unfolding protein response, such as EDEM1 and EDEM3 (Fig 7A), are reduced upon com-
pleting the RR-MBI. This suggests that the RR-MBI reduces ER-associated degradation
(ERAD) activity. Interestingly, upregulation of markers of ERAD activity such as EDEM1 has
been observed in actively inflamed IBD [46].
Among the genes that are upregulated in response to the RR-MBI in IBD patients is a key
transcriptional regulator for generating quiescent naïve T cells, FOXP1 [47] (Fig 7A). Reduced
FOXP1 expression leads to T cell proliferation and activation which is directly involved in im-
mune response and inflammation linked to IBD. Thus, it appears that RR-MBI-mediated upre-
gulation of FOXP1 may reduce T cell activation and potentially attenuate inflammation.
Similarly, enhanced expression of IRF7 (Fig 7A), a transcriptional regulator of interferon ex-
pression, in response to the RR-MBI may limit the inflammatory sequelae of IBD [48]. Another
upregulated gene of interest is STAT5B (Fig 7A). STAT5B expression is reduced in the colon of
Crohn’s disease patients and STAT5B deficient mice are more susceptible to colitis [49].
Fig 7. Transcriptional changes and pathwaysmodulated pre- to post-RR-MBI among IBD patients. A) Heatmap of selected differently expressed
genes identified by comparing pre- to post-mind body intervention transcriptional profiles of IBD patients. Gene expression is shown with a pseudocolor scale
(-1 to 1) with red color denoting increased fold change in gene expression and green color denoting decrease. The rows represent the genes and columns
represent individual subjects in IBD group. B) Venn Diagram depicting common genes between IBS and IBD. Only 13 genes were commonly altered
between IBS and IBD. C) Top pathways significantly affected by differentially expressed genes in IBD group. The statistical significance of effect on
pathways was calculated using Fisher’s Exact Test. The pathways with P value <. 05 were considered significantly effected. Each bar represents a
significantly enriched pathway. The p value is depicted as −log10 (p value) on the x-axis.
doi:10.1371/journal.pone.0123861.g007
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STAT5B has been postulated to reduce inflammation and to play a protective role in inflamma-
tion. STAT5B activation increases the suppressor function of regulatory T cells (Tregs) while
inhibiting effector T cells (Teffs); furthermore, a reduction in Tregs has been observed in IBD
[50]. Thus, the increase in STAT5B expression in response to the RR-MBI in IBD patients may
reduce inflammatory processes and enhance Treg function in IBD. MX1 (Fig 7A) is also upre-
gulated by the RR-MBI in IBD patients. MX1 downregulation has been shown to lead to in-
creased cytokine and chemokine production concomitant with recruitment of monocytes and
granulocytes and an increase in inflammation [51].
Comparing the differentially-expressed genes in the two patient groups demonstrated that
13 transcripts were affected by the RR-MBI in both IBS and IBD patients, as shown in the
Venn diagram in Fig 7B. The list of 13 genes affected in common (S3 Table) includes genes al-
ready linked with IBD (e.g., FKBP5, ITGB3).
Gene ontology (GO) enrichment analysis with DAVID identified ATP nucleotide binding,
cellular processes, cell death/apoptosis, immune system processes, immune cell activation, reg-
ulation of immune system, kinase activity, glucose metabolism, and stress response as GO cate-
gories with highly significant overrepresentation of differentially expressed genes (Table 4).
Most interestingly in the context of IBD and the RR-MBI, leukocyte, T cell and B cell activa-
tion, as well as NF-κB regulation, immune and defense responses and cellular response to stress
were significantly affected biological processes. Unlike the IBS group, genes with significant
changes in expression in the IBD group were not linked to cell cycle and cellular movement
related processes.
IPA analysis of the differentially expressed genes in IBD following the RR-MBI revealed sig-
nificant enrichment for cellular growth and proliferation (e.g., ERK5 Signaling, ERK/MAPK,
RhoA, Integrin, P53, Cdc42, and Actin-cytoskeleton signaling), inflammation and stress re-
sponse (e.g., IGF1 and glucocorticoid receptor signaling, and NRF2-mediated oxidative stress
response), as well as insulin-signaling related pathways (Fig 7C).
Interactive network analysis of RR-MBI-induced gene expression changes in IBD identi-
fies networks and key nodes related to cell morphology, inflammation and apoptosis. In-
teractive network analysis with the Ingenuity Knowledge Base (Qiagen) identified>20
significantly (i.e., score>20) altered interactive networks linked to cell morphology and tissue
development, apoptosis and inflammation. Networks with related functions were merged to
generate an integrated picture of biological relationship for better understanding of the under-
lying mechanism of changes associated with an RR-MBI. We merged the networks “cell and
tissue morphology,” “apoptosis,” “hematological,” and “inflammation” to generate a global
overview of the effect of the RR-MBI on IBD (Fig 8). The genes altered by the RR-MBI in IBD
were mostly (~85%) downregulated, suggesting that the RR-MBI serves to downregulate or in-
hibit apoptosis and inflammation related processes. On the basis of network analysis, key focus
hubs included: UBC, NF-κB, ERK1/2, MAPK8, MAPK, p38 MAPK, MAP3K7 and APP.
RR-MBI downregulates gene sets related to cell cycle and the immune system in IBD.
GSEA analysis identified 60 pathways that were significantly (p<0.005, FDR<0.075) altered
following the RR-MBI (S3 Fig). The significantly altered pathways include a cluster related to
cell cycle (e.g., mitotic cell cycle, G1 phase, G2 phase, G1-G2-M phase, P53 signaling), apopto-
sis (e.g., apoptosis, BAD pathway), immune system (e.g., TLR, IFN, TNFR1, PPARA,
P38MAPK, IL1R pathways), extracellular matrix related pathways (e.g., TGFB and BMP), insu-
lin, and hypoxia. Further to identify the core subset of genes from significantly enriched gene-
sets that is strongly associated with effect of the RR-MBI on IBD, we performed leading edge
analysis. As noted above, leading edge analysis identifies a core subset of genes that accounts
for the enrichment signal, which can lead to hypotheses about the biological mechanism of the
intervention. Leading edge analysis identified multiple cell cycle and apoptosis-related
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Table 4. Gene-Ontology (GO) enrichment analysis of genes altered in IBD patients after the RR-MBI.
Major GO Cluster Enrichment Score Selected Processes P value
IBD
ATP and Nucleotide Binding 5.99
Nucleotide binding 1.45E-08
ATP binding 5.52E-07
Protein serine/threonine kinase activity 2.44E-06
Protein transport 5.46
Cellular process 4.42
Primary metabolic process 2.39E-07
Nucleobase, nucleoside, nucleotide and nucleic acid metabolic process 4.73E-04
Negative regulation of cellular process 4.25 Negative regulation of transcription 2.45e-05
Cell death/apoptosis 3.66
Regulation of apoptosis 7.93E-06
Regulation of programmed cell death 1.07E-05
Induction of apoptosis 0.037
Induction of programmed cell death 0.038
Macromolecule catabolic process 2.88
Cellular protein catabolic process 1.31E-04
Ubiquitin-dependent protein catabolic process 2.84E-04
Protein ubiquitination 0.005
Regulation of kinase activity 2.71
Regulation of protein kinase activity 0.003
Regulation of MAP kinase activity 0.019
Nucleoside-triphosphatase activity 2.55
ATPase activity 0.050
Immune system process 2.42
Regulation of immune system process 5.25E-05
Regulation of myeloid cell differentiation 1.19E-04
Immune cell activation 2.39
Leukocyte activation 4.44E-05
T cell activation 0.019
B cell activation 0.030
Vesicle-mediated transport 2.24
Vesicle-mediated transport 8.12E-05
Regulation of binding 2.2
Positive regulation of binding 0.001
Positive regulation of NF-κB transcription factor activity 0.010
Regulation of immune system process 2
Positive regulation of immune response 0.010
Positive regulation of defense response 0.024
Glucose metabolism 2
Energy reserve metabolic process 0.004
Glucose metabolic process 0.016
Stress response 1.97
Cellular response to stress 0.002
Response to stress 0.010
The enrichment score for each biological group indicates its importance (enrichment) and was calculated by taking the geometric mean of enrichment p-
values (EASE scores) for each GO term associated with the gene members in the group. An enrichment score of 2 is equivalent to a non-log p-value of
0.01.
doi:10.1371/journal.pone.0123861.t004
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molecules (MAPK1, CCND1, MAP2K1, MAPK8) as associated with the RR-MBI (Fig 9A). All
of these molecules were significantly downregulated after the RR-MBI (Fig 9B). Some of these
molecules were also identified as key focus molecules related to cell cycle and apoptosis
(MAPK, MAPK8, MAP3K7) in the interactive network analysis.
Fig 8. Network representation of the biological functions significantly altered by 8-weeks of RR-MBI in IBD patients.Networks shown: A) Cellular
morphology and tissue development related genes with UBC, MAPK8, NF-κB and ERK1/2 as primary regulatory nodes; B) Genes involved in cell death,
apoptosis and inflammation with UBC, APP and IRF7 as a critical regulatory node. We used the Ingenuity Pathways Analysis tool (IPA 8.0) to generate the
networks of genes altered by RR-MBI in IBD patients and merged the major networks with obvious related functions. Each node represents a gene and each
edge represent a molecular interaction. The intensity of the node color indicates the degree of upregulation (red) and downregulation (green), while white
nodes indicate non-modified genes that may be affected in a non-transcriptional manner.
doi:10.1371/journal.pone.0123861.g008
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Discussion
While genetic predisposition, microbiome, and transcriptional profiling studies in IBS and IBD
have indicated a role of oxidative stress related pathways [52–56], little progress has been made
exploring the beneficial effects of mind-body interventions (MBIs) in these diseases. Our group
has previously shown that regular elicitation of the relaxation response (RR) alters the expres-
sion of inflammatory molecules [27,28]. Building on these findings, we performed what we be-
lieve to be the first study to determine psychological, inflammatory, and genomic markers of a
mind-body intervention in a combined group of patients with IBS and IBD.
In this open, uncontrolled study of an RR-MBI for GI disorders, mixed groups of patients
with IBS and IBD jointly participated in a 9-week group intervention. In both IBS and IBD pa-
tients, trait anxiety decreased significantly over the course of the intervention; this improve-
ment was maintained during the follow-up period. Pain catastrophizing also decreased
significantly in both IBS and IBD patients but, interestingly, the timing was different: Whereas
IBD patients had significantly decreased pain catastrophizing at the end of the intervention
which was maintained during the follow-up period, IBS patients did not have significantly de-
creased pain catastrophizing scores until the completion of the follow-up period. There were
also improvements in disease-specific measures of both symptom severity (for IBS) and quality
of life (for both IBS and IBD). These findings suggest that an RR-MBI can be effective in de-
creasing distress and improving quality of life in both IBS and IBD.
The combined clinical group exposure to an MBI was a unique way to streamline resources
for seemingly disparate clinical populations. Because the financial resources and access to per-
sonnel needed to deliver behavioral interventions are often lacking in GI clinics, it is common
for these treatments to be unavailable. The group setting allows for more resource-efficient de-
livery of care to a broader audience of patients with gastrointestinal disorders but, despite the
evidence presented here for its value, it continues to be unclear whether it provides the same
benefits as individual treatment.
In addition to improvements on self-report measures, our data provide the first evidence
that an RR-MBI in IBS and IBD patients is associated with specific gene expression changes.
Although many of the RR-specific gene expression changes differed significantly between IBS
and IBD patients and significantly more gene expression changes were observed in IBD than in
Fig 9. Identification of potential key genes responsible for delivering the beneficial effects of RR-MBI
in IBD identified using Gene Set Enrichment Analysis and leading edge analysis. A) Bar graph
depicting the abundance of genes in significantly enriched geneset (S2 Fig). B) Heatmap of most abundant
genes in IBD patients depicting the pattern of downregulation after the RR-MBI.
doi:10.1371/journal.pone.0123861.g009
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IBS, changes in upstream and downstream targets of NF-κB (e.g. MAPK, P38 MAPK,
MAPK8) after the RR-MBI were common to both IBS and IBD, supporting the notion that RR
elicitation may counteract the effects of stress on IBS and IBD through common changes in
stress-related gene expression. There is a growing understanding of central (i.e., brain) changes
brought about by behavioral interventions in GI disorders. For example, Lowen et al. recently
demonstrated that the abnormal processing and enhanced perception of visceral stimuli in IBS
can be normalized by both hypnotherapy and an educational intervention [57]. It is also
known that placebo can produce adequate relief of IBS symptoms and this is a limitation to our
study design with respect to IBS. In one study serum levels of TNF-related weak inducer of ap-
optosis (TWEAK) at baseline were higher (p = 0.0144) in IBS patients who reported adequate
relief and in particular in those who received the placebo treatment [58]. This suggests that
modulation of inflammation and apoptosis may be common to brain-based improvements in
IBS, including those related to placebo. The transcriptome changes we demonstrate here sug-
gest a mechanism by which MBIs can bring about concomitant peripheral changes.
Despite clear changes in both quality of life and gene expression with the RR-MBI, there
were no clear changes in ESR and CRP, commonly used markers of gross inflammation. ESR
and CRP are relatively blunt markers of active inflammation and frequently respond rather
slowly to changes in inflammatory processes. For the IBS patients, who suffer from a disorder
that does not involve gross inflammation, it may not be surprising that these markers showed
no changes. For the IBD patients, who suffer from a disorder that does involve gross inflamma-
tion, the key may have been their inflammatory state before and during the study. They were
clinically stable—in remission from severe inflammation despite the fact that they were still
suffering from symptoms related to IBD. (Indeed, clinically there can often be a disconnect be-
tween gross inflammation and symptoms in IBD.) More specific markers, such as fecal calpro-
tectin or lactoferrin, responsive to more subtle inflammatory changes, may be able to reveal
underlying changes, whether for IBD in remission or for hypothesized micro-inflammation in
IBS. In future studies, use of placebo control conditions and specific inflammatory markers will
be used. The choice of such markers could be informed both by advances in the understanding
of inflammation in IBS and IBD and by the inflammation-related genomics findings we
report here.
The comparison of baseline gene expression profiles of IBS and IBD groups indicated signif-
icant differences in the expression profile of genes linked to inflammation, suggesting that the
IBD and IBS populations differ in baseline levels of inflammatory component compared. Asso-
ciated with an RR-MBI and concomitant daily RR elicitation, transcriptome changes were
identified in both the IBS and IBD groups. Some of these transcriptome changes, including
those in inflammation and immune pathways, overlap with transcriptome changes induced by
RR elicitation in a healthy population [27,28]. This suggests that the RR modulates a core set of
common inflammation and immune pathways in both healthy and disease populations as one
mechanism by which it has its beneficial effects specifically in IBD population.
In IBD patients, the RR-MBI reduced expression of various genes that are directly involved
in key pathophysiological processes and pathways linked to IBD development and progression.
This included a whole set of genes linked to interferon regulation and signaling, genes associat-
ed with inflammation, endothelial barrier functions, vascular permeability, neutrophil recruit-
ment, and leukocyte adhesion and extravasation, innate immune response genes, T cell
differentiation genes as well as several ER stress markers. Most importantly, the direction of
the expression changes of these genes impacted by the RR-MBI appears to counter the inflam-
mation and immune system disturbances observed in IBD and is expected to dampen the
deregulated immune responses.
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In the IBS group, participation with the RR-MBI was significantly associated with changes
in a network enriched in genes linked to the cell cycle, cellular proliferation and inflammation;
the NF-κB complex, MAPK and TNF were key focus molecules suggesting their key role in re-
laying effects of RR in the IBS population.
Similar Interactive network analysis in the IBD group network focus hubs are formed by in-
flammation-related genes (e.g., NF-κB) and kinases (e.g. ERK1/2, MAPK8, MAPK, MAP3K7).
The genes forming focus hubs are considered the most critical for the overall function of the
network. This suggests that NF-κB activity, along with altered expression of its up- and down-
stream regulators, was central to the changes associated with the RR-MBI. Multiple studies
have shown that enhanced NF-κB activity leads to increased expression of multiple cytokines
that play a central role in the onset and progression of IBD [59]. The interactive network analy-
sis shows that most of target genes for key focus molecules are downregulated by RR elicitation
in IBD population, suggesting a parallel decrease in inflammation.
To further refine and strengthen our finding, we performed a complementary analysis using
GSEA on the transcriptome changes in IBS and IBD subjects, which resulted from participation
in an RR-MBI. In IBS patients GSEA analysis identified significant upregulation of multiple cell
cycle related DNA Repair and mRNA processing pathways (S2 Fig). On the other hand, in IBD
patients GSEA analysis identified significant downregulation of multiple cell cycle-, immune sys-
tem- and apoptosis-related pathways, corroborating the results from the traditional individual
gene based analysis. Further analysis of genes from these pathways identified multiple NF-κB
upstream kinases (MAPK1, MAP2K1, MAPK8) as molecules that may be associated with effects
of an RR-MBI. Studies using both gene expression profiling and protein-based assays have
shown activation of Mitogen-activated protein kinases (MAPK) to be important in IBD [59].
AN RR-MBI might be relaying its beneficial effects by downregulating expression or deactivating
MAPK in such a way that multiple pro-inflammatory cytokines are downregulated.
This single-center, uncontrolled, open-label study of a multimodal intervention has inher-
ent limitations. First among these is a limitation common to any multimodal intervention such
as the RR-MBI used here, namely, the inability to pinpoint any particular component of the in-
tervention (e.g., RR-elicitation practice, building cognitive skills, or interaction with a group of
fellow sufferers) as the “active ingredient.” Future work will be needed to determine whether
certain components of the intervention are more important than others or whether the compo-
nents combine to provide synergistic benefit. Furthermore, without the benefit of a randomized
trial, it is impossible to say more than that the changes reported here are associated with partic-
ipation in the RR-MBI. Still, the findings here do provide a first look at the effects MBI in gen-
eral may have on psychological, inflammatory and genomic markers in IBS and IBD patients.
Although our gene expression data was drawn from peripheral blood and not from either the
brain or gut (where one would expect the interface between MBI and GI disorders), a growing
body of evidence suggests the ability of mind-body and other behavioral interventions [27–30]
to affect gene expression in peripheral blood mononuclear cells. Furthermore, there is evidence
that peripheral blood gene expression is moderately correlated with gene expression levels in
other tissues, including brain [60,61]. This correlation may permit identification of promising
PBMC biomarkers for stress-related neuroimmunological disorders and their mind body man-
agement [62]. These results provide a platform for starting clinical trials to validate the role of
focus genes and pathways in delivering the beneficial effects of RR-MBI in IBS and IBD.
Conclusion
In this uncontrolled pilot study, improvement in symptoms and quality of life in IBS and IBD pa-
tients was associated with receiving a group RR-MBI.With scarce health care resources, especially
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in the administration of psychological interventions, a group setting delivery to a wider GI popula-
tion may be cost effective. Specific alterations in gene expression, impacting key immune process-
es and inflammatory pathways linked to IBD, were induced by the RR-MBI, suggesting that an
RR-MBI may elicit not only beneficial psychological effects, but also pathophysiological effects on
inflammatory pathways directly involved in IBDmanifestations.
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